Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy Of Tocotrienol a Natural Vitamin E In Biopsy Wound (TOP/OTOP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01579227
Recruitment Status : Unknown
Verified January 2017 by Chandan K Sen, Ohio State University.
Recruitment status was:  Active, not recruiting
First Posted : April 17, 2012
Last Update Posted : January 29, 2018
Sponsor:
Collaborator:
Carotech Inc.
Information provided by (Responsible Party):
Chandan K Sen, Ohio State University

Tracking Information
First Submitted Date April 13, 2012
First Posted Date April 17, 2012
Last Update Posted Date January 29, 2018
Study Start Date January 2012
Estimated Primary Completion Date December 2018   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: January 21, 2014)
WOUND CLOSURE [ Time Frame: 1-2 month(s) ]
Wound closure will be assessed by results of conventional camera and thermal imaging in Group 1 and Group 2 subjects.
Original Primary Outcome Measures Not Provided
Change History
Current Secondary Outcome Measures
 (submitted: January 21, 2014)
SCARRING [ Time Frame: 1-2 month (s) ]
Scarring will be assessed in group 1 and group 2 subjects by the Vancouver Scar Scale (VSS). Scoring will be performed by three blinded observers. The VSS evaluates vascularity (redness), height (hypertrophy), pliability (contracture and elastic texture) and pigmentation.
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures
 (submitted: August 21, 2014)
Wound closure and Increased Angiogenesis [ Time Frame: 1-2 months ]
Test whether miR-200b is silenced with tamoxifen resulting in increased angiogenesis and faster wound closure
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Efficacy Of Tocotrienol a Natural Vitamin E In Biopsy Wound
Official Title Efficacy Of Tocotrienol a Natural Vitamin E In Biopsy Wound.
Brief Summary

The following two objectives are proposed in healthy subjects to characterize (1) wound closure, (2) scar formation/appearance, and (3) inflammatory response:

Objective 1, (topical only - referred to as "TOP") - Topical application of Tocotrienol (TCT) vs placebo in bilateral punch biopsy

Objective 2, (oral and topical - referred to as "OTOP") - Combined oral supplementation and topical application of tocotrienol (TCT) vs placebo in bilateral punch biopsy

Objective 3, (topical only - referred to as "TAM") - Topical application of tamoxifen vs placebo in bilateral punch biopsy.

Objective 4, (topical only to normal skin) - Topical application of TCT vs placebo on bilateral lets on normal skin.

Detailed Description
  • In nature, the vitamin E family is split into two classes: tocopherols (TCP) and tocotrienols (TCT). Members of the TCP and TCT family are biologically unique.

    • TCP are mainly found in green leafy vegetables while TCT are the primary vitamin E of seeds, including cereal grains such as wheat, rice, and barley.
  • Vitamin E is thought to improve wound healing by inhibiting collagen synthesis and attenuating fibroblast proliferation and inflammation. However, outcomes based scientific literature on the therapeutic efficacy of vitamin E in skin wound closure is scant and has primarily focused on TCP.

    • Oral supplementation of TCP showed modest improvement in rodent wound closure, but the relevance of oral TCP supplementation in rats already receiving high dose vitamin E in a standard laboratory is questionable.
    • Topical TCP on surgical wounds of children have been shown to improve wound healing; yet no mechanistic basis for the observed effect was described.
  • Preliminary observations from the PI's active IRB protocol to test TCT in scar appearance of surgical wounds led us to evaluate the potential of TCT vitamin E to improve wound closure in healthy subjects. To date, the therapeutic efficacy of TCT in either topical (TOP) or oral with topical (OTOP) applications for skin wound healing remains to be reported.

    • Preliminary observations also made show down-regulation of microRNA-200b supports cutaneous angiogenesis, the most important step in cutaneous wound healing. Tamoxifen silences mircroRNA-200b and later work has recognized that under non-neoplastic conditions, tamoxifen may induce angiogenesis.
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples With DNA
Description:
Tissue biopsy will be collected twice in the study period.
Sampling Method Probability Sample
Study Population We plan to recruit 27 healthy adult subjects for the TOP group, 34 healthy adult subjects for the OTOP group,10 healthy adult subjects for the TAM group and 30 healthy subjects for Normal Skin.
Condition Scar
Intervention
  • Device: Topical Tocotrienol (TCT)
    Natural Form Vitamin E topical cream(TCT)
    Other Name: TCT
  • Dietary Supplement: Oral Tocotrienol Capsules (TCT)
    Natural Form Vitamin E Oral capsules (TCT)
    Other Name: TCT
  • Device: Tamoxifen Cream
    Tamoxifen cream
  • Device: Placebo cream
    Placebo cream
    Other Name: Placebo
  • Dietary Supplement: placebo capsule
    placebo capsule
    Other Name: placebo
Study Groups/Cohorts
  • 1-TOP group 1
    TOP group 1 will have biopsy #2 collected 3 days after 1st biopsy collected.
  • TOP group 2
    TOP group 2 will have biopsy #2 collected 30 days after 1st biopsy collected.
  • OTOP group-1
    OTOP will use topical cream (either topical tocotrienol (TCT) or placebo cream) as well as oral supplementation (either oral Tocotrienol capsules (TCT) or placebo capsules). OTOP group 1 will have biopsy #2 collected 3 days after 1st biopsy collected.
    Interventions:
    • Device: Topical Tocotrienol (TCT)
    • Dietary Supplement: Oral Tocotrienol Capsules (TCT)
    • Device: Placebo cream
    • Dietary Supplement: placebo capsule
  • OTOP group-2
    OTOP will use topical cream (either topical tocotrienol (TCT) or placebo cream) as well as oral supplementation (either oral Tocotrienol capsules (TCT) or placebo capsules). OTOP group 2 will have biopsy #2 collected 30 days after 1st biopsy collected.
    Interventions:
    • Device: Topical Tocotrienol (TCT)
    • Dietary Supplement: Oral Tocotrienol Capsules (TCT)
    • Device: Placebo cream
    • Dietary Supplement: placebo capsule
  • TAM Group 1
    TAM group 1 will have #2 biopsy collected 21 days after 1st biopsy collected. Tamoxifen cream and placebo cream will be applied where biopsies are collected from 1 week prior to having the biopsy procedure until the second biopsy is collected (21 days later).
    Intervention: Device: Tamoxifen Cream
  • Normal Skin
    Placebo group will apply placebo and TCT cream that will be applied daily to a specified area on the subjects legs (normal skin) for 5 weeks. One leg will be applied with placebo and the other will be applied with TCT cream. Subjects will return weekly for 5 weeks, where non-invasive measurements using Laser Speckle imaging, will be completed at each study visit
    Interventions:
    • Device: Tamoxifen Cream
    • Device: Placebo cream
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Unknown status
Estimated Enrollment
 (submitted: March 16, 2016)
101
Original Estimated Enrollment
 (submitted: April 16, 2012)
71
Estimated Study Completion Date December 2018
Estimated Primary Completion Date December 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Ages- 18-50 (Both Male & Female)
  • Non-smoker - having quit at least 3 months prior to enrollment
  • Non-diabetic
  • Non-pregnant or non-breastfeeding - verbal assent.
  • If a female subject of childbearing age misses her menstrual period after the start of the study, she will inform the investigators and be given a pregnancy test to ensure, for safety reasons, that she is not pregnant. If she is pregnant, she will discontinue participation in the study.
  • No current use of OTC medications or other form of supplements containing vitamin-E

Exclusion Criteria:

  • Diabetes or HIV diagnosis
  • Alcohol or drug abuse
  • unable to provide informed consent
  • Therapeutically anti-coagulated
  • Prisoner
  • Currently prescribed immunosuppressant medication
Sex/Gender
Sexes Eligible for Study: All
Ages 18 Years to 50 Years   (Adult)
Accepts Healthy Volunteers Yes
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT01579227
Other Study ID Numbers 2011H0286
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Chandan K Sen, Ohio State University
Study Sponsor Chandan K Sen
Collaborators Carotech Inc.
Investigators
Principal Investigator: Chandan K Sen, PhD Ohio State University
PRS Account Ohio State University
Verification Date January 2017